N-naphthoyl-beta-naltrexamine (NNTA), a highly selective and potent activator of μ/kappa-opioid heteromers - Wikidata - awgldk - TriplyDB

N-naphthoyl-beta-naltrexamine (NNTA), a highly selective and potent activator of μ/kappa-opioid heteromers

N-naphthoyl-beta-naltrexamine (NNTA), a highly selective and potent activator of μ/kappa-opioid heteromers

http://www.wikidata.org/entity/Q34169318

about

Clinically employed opioid analgesics produce antinociception via μ-δ opioid receptor heteromers in Rhesus monkeys The δ opioid receptor agonist SNC80 selectively activates heteromeric μ-δ opioid receptors Novel GPCR paradigms at the μ-opioid receptor Putative kappa opioid heteromers as targets for developing analgesics free of adverse effects.Pharmacologic characterization in the rat of a potent analgesic lacking respiratory depression, IBNtxA.Synthesis and evaluation of aryl-naloxamide opiate analgesics targeting truncated exon 11-associated μ opioid receptor (MOR-1) splice variants.Revolution in GPCR signalling: opioid receptor heteromers as novel therapeutic targets: IUPHAR review 10.Discovery of GPCR ligands for probing signal transduction pathways.In vivo opioid receptor heteromerization: where do we stand?GPCR Heterodimerization in the Reproductive System: Functional Regulation and Implication for Biodiversity Synthesis of novel triplets with a 1,3,5-trioxazatriquinane skeleton and their pharmacologies for opioid receptors.Allosteric interactions between δ and κ opioid receptors in peripheral sensory neurons Opioid activity of spinally selective analogues of N-naphthoyl-β-naltrexamine in HEK-293 cells and mice.Synthesis and characterization of a dual kappa-delta opioid receptor agonist analgesic blocking cocaine reward behavior Synergism between a serotonin 5-HT2A receptor (5-HT2AR) antagonist and 5-HT2CR agonist suggests new pharmacotherapeutics for cocaine addiction.Novel 6β-acylaminomorphinans with analgesic activity.Bivalent ligands that target μ opioid (MOP) and cannabinoid1 (CB1) receptors are potent analgesics devoid of tolerance.G Protein-Coupled Receptor Heteromers.Pharmacological Profiles of Oligomerized μ-Opioid Receptors.History and biological significance of GPCR heteromerization in the neuroendocrine system.G-protein-coupled receptor type A heteromers as an emerging therapeutic target.Breaking barriers to novel analgesic drug development.Synthesis and Investigation of Mixed μ-Opioid and δ-Opioid Agonists as Possible Bivalent Ligands for Treatment of Pain.Structure activity relationship studies of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan (NAQ) analogues as potent opioid receptor ligands: preliminary results on the role of electronic characteristics for Basic/Translational Development of Forthcoming Opioid- and Nonopioid-Targeted Pain Therapeutics.Detection of Receptor Heteromerization Using In Situ Proximity Ligation Assay.Inner Workings: Safer opioids may be on the horizon, but mitigating addiction is a long shot

P2860

Q24597777-4A581536-7F5A-40A4-A7F2-A5FDDBBE23CB Q24630886-35F51ED6-411D-424F-9446-A315A623CCAC Q26864286-81A7A3FC-A03B-48FF-AB3F-49A560DEDE74 Q34061067-6C3845C7-0B4A-417A-81F3-238000780817 Q34125112-6FCACD64-B5EB-413A-8872-9B1C322D229A Q34284204-0AC6FC42-78F5-46CF-8219-18B54B11EE64 Q34424009-FDD3ABB3-6523-430C-A7C6-A659D6B32716 Q34582707-B1158CA3-4DB1-48BA-8766-D82E6D8D2F57 Q34939677-AC391A60-BB67-4711-AFA4-0390BD4FE869 Q34962059-86E382EA-80F2-435C-B3ED-966F02EDE4AE Q35627652-F97D4500-9797-4C06-A36A-4488A97ACC34 Q35688476-0A86B408-D868-4941-9E69-8F92B45E29F7 Q36225640-D50B94E5-4190-4CC0-AAD2-CE41567CDD69 Q36296493-4E7B33E9-AB14-4136-A5F6-CFAA76901A03 Q36540945-41C9BA20-19C6-4389-B13C-D26908A9EB73 Q37340566-367EB22C-1423-45BD-88B9-1752D9AC364B Q37360643-C9AB7BB3-666D-451E-8EDA-AD414D6DCA8D Q37489251-898E7433-4CBD-4C0A-B75F-4ED4A18F943B Q37679197-25321F98-3445-4278-9042-665793E1670C Q37966715-780C8FAE-4EF4-455D-B238-118A87C886E3 Q38266283-CA9BF2FD-0936-4307-9858-11E6CDC7A7AD Q39360773-FB84F0B7-1091-4406-BB9A-352E31C95B6C Q41411764-C285D2D0-7A1C-4953-9F4A-8ECF3F60896B Q42633385-0FA9A02C-F964-4BE8-8C91-A8D492A4CC58 Q43075742-5DA2E668-E654-493D-AB5E-F8890B46A716 Q49754648-5195A2A2-1A01-40D2-B461-3AC21C578F04 Q58781851-58BE0FCE-D332-448E-A1C2-5A33BD555472

P2860

N-naphthoyl-beta-naltrexamine (NNTA), a highly selective and potent activator of μ/kappa-opioid heteromers

http://www.wikidata.org/entity/Q34169318

description

2011 nî lūn-bûn

@nan

2011 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մարտին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

N-naphthoyl-beta-naltrexamine ...... r of μ/kappa-opioid heteromers

@ast

N-naphthoyl-beta-naltrexamine ...... r of μ/kappa-opioid heteromers

@en

N-naphthoyl-beta-naltrexamine ...... r of μ/kappa-opioid heteromers

@nl

type

label

N-naphthoyl-beta-naltrexamine ...... r of μ/kappa-opioid heteromers

@ast

N-naphthoyl-beta-naltrexamine ...... r of μ/kappa-opioid heteromers

@en

N-naphthoyl-beta-naltrexamine ...... r of μ/kappa-opioid heteromers

@nl

prefLabel

N-naphthoyl-beta-naltrexamine ...... r of μ/kappa-opioid heteromers

@ast

N-naphthoyl-beta-naltrexamine ...... r of μ/kappa-opioid heteromers

@en

N-naphthoyl-beta-naltrexamine ...... r of μ/kappa-opioid heteromers

@nl

P1433

Q34169318-15BCD95E-D259-415C-8A85-07713BF22FBB

P1476

Q34169318-CC86B99C-63AA-42F1-B695-5622422AA76E

P2093

Q34169318-22124023-C376-4932-B9F4-2B79BA68454B

Q34169318-26AA142C-34A0-40E0-A41C-1B156672D167

Q34169318-4E415CC0-EC32-44E7-BFA5-CABE7B70DEDC

Q34169318-6AD06A29-0B62-469B-8D7B-D1352E860FAB

Q34169318-7AFD4F9A-5120-42C8-A5E4-937CB7112163

Q34169318-88B6894A-8430-4F59-ACF5-C918E761A3E4

Q34169318-D39BCF75-50B7-42C3-9057-DFA1E81DF0CE

P2860

Q34169318-00F98C3C-1BE3-4842-8AF6-44657A6A997E

Q34169318-0403326C-C805-41BF-B0CA-6961E23BC214

Q34169318-17004751-F299-4443-98EB-601F19B12111

Q34169318-1D387C75-2FAA-4EEF-B1AB-86364A3BD292

Q34169318-25C883E5-8DFA-4B80-970B-64EC8D601FCD

Q34169318-270E4825-A1B4-493D-8C45-9735639547DE

Q34169318-29637A63-6691-4B53-A1EF-B3D516778077

Q34169318-3D58BC87-2F63-405F-82F8-ED6BF5F73145

Q34169318-46056807-0A6E-463C-A2B7-79A3BD189E44

Q34169318-49779D4B-D56B-4B91-A365-9C4B25C7D1BE

P304

Q34169318-5C3E7934-8270-43D4-AD3E-B8B1711EC8AA

P31

Q34169318-3F326639-41CE-47FC-AC88-DEE5A29FDB30

P356

Q34169318-DB4BE3FC-3C8D-4929-A53A-6E9C439EF614

P407

Q34169318-6B14EA39-C892-44BA-A4B9-84025C5648C2

P433

Q34169318-5DA6AB4C-E4F4-489D-B7FF-E4ACFBE28358

P478

Q34169318-25295684-95DD-46A8-B1D9-FED47A82B717

P577

Q34169318-8E37B797-BB47-4751-9B38-5021110A0EFD

P5875

Q34169318-54BA4A85-CEBA-4E62-8F20-F5EAA2F3CBB0

P698

Q34169318-BB17AB34-55D8-4CC2-B14C-F8681CA66911

P921

Q34169318-61ab2254-6215-465f-b9f9-21f28355cde7

P932

Q34169318-A1355EC3-6CE8-4C6B-AD92-782FF4ABC911

P356

PNAS.1016277108

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

N-naphthoyl-beta-naltrexamine ...... r of μ/kappa-opioid heteromers

@en

P2093

Ajay S Yekkirala

http://www.w3.org/2001/XMLSchema#string

Alexander E Kalyuzhny

http://www.w3.org/2001/XMLSchema#string

Christopher R McCurdy

http://www.w3.org/2001/XMLSchema#string

Mary M Lunzer

http://www.w3.org/2001/XMLSchema#string

Michael D Powers

http://www.w3.org/2001/XMLSchema#string

Philip S Portoghese

http://www.w3.org/2001/XMLSchema#string

Sandra C Roerig

http://www.w3.org/2001/XMLSchema#string

P2860

A heterodimer-selective agonist shows in vivo relevance of G protein-coupled receptor dimers.

G-protein-coupled receptor heterodimerization modulates receptor function

Standard opioid agonists activate heteromeric opioid receptors: evidence for morphine and [d-Ala(2)-MePhe(4)-Glyol(5)]enkephalin as selective μ-δ agonists

Heterodimerization of mu and delta opioid receptors: A role in opiate synergy

Heterodimerization of opioid receptor-like 1 and mu-opioid receptors impairs the potency of micro receptor agonist

Design, synthesis, and biological evaluation of 6alpha- and 6beta-N-heterocyclic substituted naltrexamine derivatives as mu opioid receptor selective antagonists.

Minireview: Insights into G protein-coupled receptor function using molecular models.

Opioid-induced tolerance and dependence in mice is modulated by the distance between pharmacophores in a bivalent ligand series

Narcotic antagonistic potency of bivalent ligands which contain beta-naltrexamine. Evidence for bridging between proximal recognition sites.

G protein coupled receptor dimerization: implications in modulating receptor function.

P304

5098-5103

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.1016277108

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

108

http://www.w3.org/2001/XMLSchema#string

P577

2011-03-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

50348079

http://www.w3.org/2001/XMLSchema#string

P698

21385944

http://www.w3.org/2001/XMLSchema#string

P921

P932

3064379

http://www.w3.org/2001/XMLSchema#string